Intravenous Vancomycin Initiation and Monitoring in Adults
Initial dosing consists of a weight‑based loading dose followed by weight‑adjusted maintenance doses. Current consensus recommends AUC/MIC‑guided therapeutic drug monitoring rather than trough‑only monitoring for serious MRSA infections. Target exposure is an AUC/MIC of 400–600 mg·h/L (assuming an MIC of 1 mg/L) to balance efficacy and nephrotoxicity risk [1][2][3][4].
Loading Dose
- 25–30 mg/kg actual body weight administered as a single IV infusion over 1–2 h.
- Loading dose is recommended to achieve target exposure rapidly, especially in patients with high creatinine clearance or severe infection [1][2].
Maintenance Dosing
- 15–20 mg/kg actual body weight every 8–12 h, adjusted for renal function.
- Dose interval and amount are individualized based on estimated creatinine clearance and prior drug levels.
- For patients with normal renal function, 15 mg/kg q12 h is common; for augmented renal clearance, q8 h may be required [1][2][5].
Monitoring Strategy
AUC‑Based Monitoring
- Preferred method per 2020 IDSA and ASHP‑IDSA‑PIDS‑SIDP consensus guidelines.
- Target AUC/MIC 400–600 mg·h/L (or 400–650 mg·h/L in some later recommendations) to optimize efficacy while reducing acute kidney injury risk [1][2][3][4].
- AUC can be estimated using two‑point Bayesian software or limited sampling (e.g., peak and trough).
- Initiation of monitoring after the loading dose is acceptable; the loading dose contributes variably to the calculated AUC depending on the magnitude of the dose [6].
Trough‑Based Monitoring (Historical)
- Prior guidelines recommended trough concentrations of 15–20 mg/L for serious MRSA infections.
- Recent evidence questions the reliability of troughs for predicting AUC and nephrotoxicity.
- Transition to AUC monitoring is encouraged to improve target attainment and safety [1][7][2].
Practical Implementation
| Step | Action | Target |
|---|---|---|
| 1 | Calculate loading dose (25–30 mg/kg) and administer IV over 1–2 h. | Immediate therapeutic exposure |
| 2 | Initiate maintenance dosing (15–20 mg/kg q8–12 h) adjusted for renal function. | Steady‑state exposure |
| 3 | Obtain two serum concentrations (e.g., 1–2 h post‑infusion and pre‑next dose) after the third dose or earlier if clinically indicated. | Input for Bayesian AUC calculation |
| 4 | Adjust maintenance dose to achieve AUC/MIC 400–600 mg·h/L. | Efficacy with minimized nephrotoxicity |
| 5 | Re‑measure AUC after any dose change, renal function change, or clinical deterioration. | Ongoing safety and effectiveness |
Pitfalls and Considerations
- Loading dose may over‑estimate AUC if renal clearance is markedly increased; Bayesian tools can account for this variability [6].
- In settings lacking Bayesian software, limited‑sampling strategies using peak and trough levels remain acceptable, but AUC targets should be derived rather than relying on trough alone [2].
- Nephrotoxicity risk increases when AUC exceeds 600 mg·h/L; dose reductions should be made promptly if higher exposures are observed [1][2].